AB Science Overview

  • Founded
  • 2001

Founded
  • Status
  • Public

  • Employees
  • 100

Employees
  • Stock Symbol
  • AB

Stock Symbol
  • Share Price
  • $9.05

  • (As of Wednesday Closing)

AB Science General Information

Description

AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 3, Avenue George V
  • 75008 Paris
  • France
+33 01 00 00 00 00

AB Science Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AB Science Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.05 $9.16 $6.10 - $15.08 $429M 46.9M 54.5K -$0.39

AB Science Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 400,491 621,598 1,068,002 260,791
Revenue 1,597 1,900 1,804 1,759
EBITDA (12,314) (13,491) (15,700) (23,120)
Net Income (18,778) (16,776) (17,150) (24,345)
Total Assets 22,548 24,083 36,515 19,872
Total Debt 17,087 9,456 8,679 2,267
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AB Science Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AB Science‘s full profile, request access.

Request a free trial

AB Science Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing o
Biotechnology
Paris, France
100 As of 2022
000.00
000000000 000.00

000000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
000000000000000
San Diego, CA
000 As of 0000
00000
000000&0

000000

a. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000000000000
Framingham, MA
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AB Science Competitors (92)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA 000 00000 000000&0
0000000 0000000000 Corporation Framingham, MA 0 000.00 000000000 000.00
0000000 Venture Capital-Backed Groningen, Netherlands 0 00.000 000
000000000 00000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
000000 00000000000 Formerly VC-backed Silver Spring, MD 000 00000 0000 00000
You’re viewing 5 of 92 competitors. Get the full list »

AB Science Patents

AB Science Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021223710-A1 Masitinib for the treatment of a multiple sclerosis patient subpopulation Pending 20-Feb-2020 0000000000
CA-3168610-A1 Masitinib for the treatment of a multiple sclerosis patient subpopulation Pending 20-Feb-2020 0000000000
AU-2020396190-A1 Use of masitinib for the treatment of eosinophilic asthma Pending 02-Dec-2019 0000000000
CA-3162956-A1 Use of masitinib for the treatment of eosinophilic asthma Pending 02-Dec-2019 0000000000
EP-3831384-A1 Use of masitinib for the treatment of eosinophilic asthma Inactive 02-Dec-2019 A61K31/496
To view AB Science’s complete patent history, request access »

AB Science Executive Team (4)

Name Title Board Seat Contact Info
Alain Moussy Chief Executive Officer & Chairman
Laurent Guy Chief Financial Officer
Christian Fassotte Global Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

AB Science Board Members (3)

Name Representing Role Since
Alain Moussy AB Science Chief Executive Officer & Chairman 000 0000
Guillemette Latscha AB Science Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

AB Science Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AB Science Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AB Science‘s full profile, request access.

Request a free trial